Efficacy of a two-component acellular pertussis vaccine in infants.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  The Pediatric Infectious Disease Journal

• Publication date

  1997-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00006454-199711000-00007PMID 9384336
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The acellular pertussis vaccine trials: an interpretation.

  1997cited by this paper
• Commentary: The best acellular pertussis vaccines are multicomponent

  1997cited by this paper
• A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.

  1996cited by this paper
• Acellular pertussis vaccines for infants.

  1996cited by this paper
• Efficacy of acellular pertussis vaccine in early childhood after household exposure.

  1996cited by this paper
• Challenges for licensure of new diphtheria, tetanus toxoid, acellular pertussis (DTaP) combination vaccines: counterpoint.

  1996cited by this paper
• A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned.

  1996cited by this paper
• A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.

  1996cited by this paper
• Comparison of 13 acellular pertussis vaccines: overview and serologic response.

  1995cited by this paper
• A placebo-controlled trial of a pertussis-toxoid vaccine.

  1995cited by this paper
• Evaluating vaccination effectiveness and vaccine efficacy by means of case-control studies.

  1994cited by this paper
• Schätzung zur Pertussisinzidenz am linken Niederrhein

  1994cited by this paper
• Pertussisdiagnostik durch Erregerisolierung mittels Direktausstrich von Nasopharyngealabstrichen

  1994cited by this paper
• Comparison of 13 acellular pertussis vaccines: adverse reactions.

  1993cited by this paper
• Efficacy of Haemophilus influenzae type b vaccines in Massachusetts children 18 to 59 months of age

  1992cited by this paper
• Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children.

  1992cited by this paper
• Acellular pertussis vaccination of 2-month-old infants in the United States.

  1992cited by this paper
• Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in US children aged 18-59 months. Haemophilus Influenzae Vaccine Efficacy Study Group.

  1991cited by this paper
• Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in US children aged 18-59 months

  1991cited by this paper
• Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions.

  1991cited by this paper
• Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial.

  1990cited by this paper
• Direct plating versus use of transport medium for detection ofBordetella species from nasopharyngeal swabs

  1989cited by this paper
• The protective efficacy of Haemophilus b polysaccharide vaccine.

  1988cited by this paper
• Pertussis Vaccines in Japan

  1988cited by this paper
• Development of a pertussis component vaccine in Japan.

  1984cited by this paper
• Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children.

  1981cited by this paper
• Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis.

  1979cited by this paper
• Letter: Epilepsy and driving.

  1974cited by this paper

• Global variations in immunisation strategies against pertussis in infancy

  2025cites this paper
• DTaP-IPV-HB-Hib vaccine (Hexaxim): an update 10 years after first licensure

  2023cites this paper
• Pertussis vaccines

  2022influential citation
• Pertussis vaccine effectiveness and duration of protection - A systematic review and meta-analysis.

  2021cites this paper
• Pertussis – die unendliche Geschichte?

  2020cites this paper
• The 112-Year Odyssey of Pertussis and Pertussis Vaccines-Mistakes Made and Implications for the Future.

  2019cites this paper
• 44 – Pertussis Vaccines

  2018cites this paper
• A New Vaccine Delivery Vehicle and Adjuvant Candidate: Bordetella pertussis Inactivated Whole Cells Entrapped in Alginate Microspheres.

  2017cites this paper
• Cell-Mediated and Humoral Immune Responses to Bordetella pertussis Inactivated Whole-Cells Encapsulated Alginate Microspheres as a New Vaccine Candidate.

  2017cites this paper
• Control selection and confounding factors: A lesson from a Japanese case-control study to examine acellular pertussis vaccine effectiveness.

  2017cites this paper
• The Pertussis resurgence: putting together the pieces of the puzzle

  2016cites this paper
• Literature Search We conducted our systematic review and meta-analysis according to the standards for intervention reviews developed by CHERG

  2016influential citation
• Pertussis: Where did we go wrong and what can we do about it?

  2016cites this paper
• Protective Effect of Contemporary Pertussis Vaccines: A Systematic Review and Meta-analysis.

  2016influential citation
• Live pertussis vaccines: will they protect against carriage and spread of pertussis?

  2016cites this paper
• Comparison of Three Whole-Cell Pertussis Vaccines in the Baboon Model of Pertussis

  2015cites this paper
• Whole ! Cell ! Pertussis ! Vaccines : ! Summary ! of ! evidence ! relevant ! to ! schedules ! 1 a . ! Burden

  2015cites this paper
• Children with Pertussis and Unvaccinated (Unprimed) Young Antigens in Vaccinated (Primed) pertussis Bordetella Antibody Response Patterns to

  2014cites this paper
• Active Surveillance of Pertussis in Infants Under 6 Months of Age: A Single Center Experience from 2011 to 2013

  2014cites this paper
• Acellular vaccines for preventing whooping cough in children.

  2014cites this paper
• Australian vaccine preventable disease epidemiological review series: pertussis, 2006-2012.

  2014cites this paper
• Licensed pertussis vaccines in the United States

  2014cites this paper
• Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology

  2014cites this paper
• Monocomponent Pertussis Toxoid Vaccine Immunologic and Epidemiologic Experience of Vaccination With a

  2013cites this paper
• 23 – Pertussis vaccines

  2013cites this paper
• The immunogenicity and safety of DTaP interchangeable immunization among Korean children.

  2012cites this paper
• Re-emergence of pertussis: what are the solutions?

  2012cites this paper
• Acellular vaccines for preventing whooping cough in children.

  2012cites this paper
• Immunoassay of Pertussis According to Ages

  2012cites this paper
• La vacunación contra pertussis: Estado actual y perspectivas futuras

  2012cites this paper
• ВАКЦИНА АБКДС-ИПВ//PRP~T: ОБЗОР 16-ЛЕТНЕГО ОПЫТА КЛИНИЧЕСКОГО ПРИМЕНЕНИЯ

  2012cites this paper
• California pertussis epidemic, 2010.

  2012cites this paper
• Acellular Pertussis Vaccine Safety and Efficacy in Children, Adolescents and Adults

  2012cites this paper
• Acellular pertussis vaccines in China.

  2012cites this paper
• Immunogenicity and safety of primary and secondary DTaP booster vaccination

  2011cites this paper
• Acellular Pertussis Booster in Adolescents Induces Th1 and Memory CD8+ T Cell Immune Response

  2011influential citation
• A DTaP–IPV//PRP∼T vaccine (Pentaxim™): a review of 16 years’ clinical experience

  2011cites this paper
• Acellular vaccines for preventing whooping cough in children.

  2011cites this paper
• Humorale und zelluläre Immunität nach Pertussis- Auffrischimpfung im Jugendalter

  2010cites this paper
• Reactogenicity of Tetanus, Diphtheria, 5-Component Acellular Pertussis Vaccine Administered as a Sixth Consecutive Acellular Pertussis Vaccine Dose to Adolescents

  2010cites this paper
• Signal detection for vaccine side effects that have not been specified in advance

  2010cites this paper
• Update on pertussis in children

  2010cites this paper
• Antibody Response Patterns to Bordetella pertussis Antigens in Vaccinated (Primed) and Unvaccinated (Unprimed) Young Children with Pertussis

  2010cites this paper
• The present and future control of pertussis.

  2010cites this paper
• Pertussis continues to put New Zealand's immunisation strategy to the test.

  2010cites this paper
• The Clinical Features of Pertussis in Infancy

  2009cites this paper
• Pertussis Vaccine: A Critique

  2009cites this paper
• Lung disease, antibodies and other unresolved issues in immune globulin therapy for antibody deficiency

  2009cites this paper
• Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination.

  2008cites this paper
• WITHDRAWN: Acellular vaccines for preventing whooping cough in children.

  2008cites this paper
• International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19–20 July 2007

  2008cites this paper
• The immunogenicity and safety of three-component DTaP vaccine in Korean infants

  2007cites this paper
• Concomitant Use of an Oral Live Pentavalent Human-Bovine Reassortant Rotavirus Vaccine With Licensed Parenteral Pediatric Vaccines in the United States

  2007cites this paper
• Is there a need for a new generation of vaccines against pertussis?

  2006cites this paper
• Diphtheria and Tetanus DTaP Toxoids and Acellular Pertussis Vaccine Adsorbed Tripedia ®

  2006cites this paper
• The Epidemiology of Pertussis: A Comparison of the Epidemiology of the Disease Pertussis With the Epidemiology of Bordetella pertussis Infection

  2005cites this paper
• Pertussis Vaccine Effectiveness Among Children 6 to 59 Months of Age in the United States, 1998–2001

  2005cites this paper
• The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins.

  2005cites this paper
• Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies

  2005cites this paper
• Infection Bordetella pertussis Pertussis With the Epidemiology of The Epidemiology of Pertussis : A Comparison of the Epidemiology of the Disease

  2005cites this paper
• Cherry Picking

  2005cites this paper
• Acellular pertussis vaccines for use among infants and young children

  2004cites this paper
• Systematic review of the effects of pertussis vaccines in children.

  2004cites this paper
• A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety.

  2004cites this paper
• DISEASE STATES AND VACCINES: SELECTED CASES

  2003cites this paper
• Vaccine Interchangeability

  2003cites this paper
• Clinical and epidemiological picture of B pertussis and B parapertussis infections after introduction of acellular pertussis vaccines

  2003cites this paper
• Analisi costo-beneficio delle campagne vaccinali per la pertosse in Friuli-Venezia Giulia

  2003cites this paper
• Pertussis: persistent pathogen, imperfect vaccines

  2003cites this paper
• Part D - Pertussis

  2003cites this paper
• Interchangeability of 2 diphtheria-tetanus-acellular pertussis vaccines in infancy.

  2002cites this paper
• Keeping pace with the elusive Bordetella pertussis.

  2002cites this paper
• Which Strategy for Pertussis Vaccination Today?

  2002cites this paper
• The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI).

  2002cites this paper
• Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine

  2002cites this paper
• Les vaccins coquelucheux : composition, tolérance, immunogénicité et efficacité. Justifications du calendrier vaccinal en France

  2001cites this paper
• Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age

  2001cites this paper
• The science and fiction of pertussis vaccines.

  2001cites this paper
• Large scale safety study of a liquid hexavalent vaccine (D-T-acP-IPV-PRP--T-HBs) administered at 2, 4, 6 and 12-14 months of age.

  2001cites this paper
• Interchangeability of vaccines

  2001cites this paper
• Pertussis Vaccines Administered in Infancy : The Italian Experience Sustained Efficacy During the First 6 Years of Life of 3-Component Acellular

  2001cites this paper
• Recent progress in clinical and basic pertussis research

  2001cites this paper
• Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine.

  2001cites this paper
• Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.

  2001cites this paper
• Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Tripedia ®

  2001influential citation
• Acellular pertussis vaccines.

  2000cites this paper
• Immunogenicity and reactogenicity of the Biken acellular pertussis vaccine in young adults.

  2000cites this paper
• Chlamydia pneumoniae viability in atherosclerotic tissue: true or false?

  2000cites this paper
• Acellular pertussis vaccines.

  2000cites this paper
• A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks following HBV at birth.

  2000cites this paper
• Hospitalization and Complications in Children under 2 Years of Age with Bordetella pertussis Infection

  2000cites this paper
• Developing better paediatric vaccines: the case of pertussis vaccine.

  1999cites this paper
• Pediatric combination vaccines.

  1999cites this paper
• Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines.

  1999cites this paper
• Adverse effects and sero-responses to an acellular pertussis/diphtheria/tetanus vaccine when combined with Haemophilus influenzae type b vaccine in an accelerated schedule

  1999cites this paper
• A ten year follow-up after immunization with a two component acellular pertussis vaccine.

  1999cites this paper
• Developing Better Paediatric Vaccines

  1999cites this paper
• Overview of recent clinical trials of acellular pertussis vaccines.

  1999cites this paper
• The science and fiction of pertussis vaccines.

  1999cites this paper
• Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine.

  1999cites this paper